MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%
Miscellaneous
EmployeesN/A
Outstanding Shares29,010,000
Market Cap$2.49 billion
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
What price target have analysts set for MOR?
10 brokerages have issued 1-year price objectives for MorphoSys' stock. Their forecasts range from €56.00 to €120.00. On average, they anticipate MorphoSys' share price to reach €94.60 in the next twelve months. This suggests that the stock has a possible downside of 4.2%. View Analyst Price Targets for MorphoSys.
What is the consensus analysts' recommendation for MorphoSys?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF) and Emerald Health Therapeutics (EMH).
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 54)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 48)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 56)
- Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)
Has MorphoSys been receiving favorable news coverage?
Media stories about MOR stock have trended somewhat positive on Thursday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MorphoSys earned a media and rumor sentiment score of 0.10 on Accern's scale. They also gave news stories about the company an impact score of 47.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for MorphoSys.
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €98.70.
How big of a company is MorphoSys?
MorphoSys has a market capitalization of $2.49 billion.
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
